

Dignity Health Arizona joins SAPPHIRE Study

SAPPHIRE-WIN female cohort to improve diagnosis and treatment for women

PERTH, Australia, 02 February 2026: Artrya Limited (ASX: AYA) (**Artrya** or the **Company**), a medical technology company commercialising its Salix® AI-powered cloud platform, for the near real time, point of care assessment and management of coronary artery disease, is pleased to announce that Dignity Health Arizona, one of the largest non-profit health systems in the United States, has agreed to in-principle participation in the retrospective U.S. multi-centre SAPPHIRE Study, subject to final documentation and their ethics approval.

John Konstantopoulos, Co-Founder and CEO of Artrya commented:

"We are pleased by Dignity Health Arizona's interest in the SAPPHIRE Study. As one of the largest health systems in the United States, with operations across 21 states¹, their participation has the potential to significantly expand the scale and impact of the study, supported by their strong leadership in cardiovascular care and research.

We are also pleased to expand the SAPPHIRE Study to include the assessment of female patients at risk of coronary artery disease, a population that is frequently asymptomatic despite the condition remaining the leading cause of death among women. Through this expansion, we aim to enhance the understanding, diagnosis and treatment of cardiovascular disease in women using Salix® and our proprietary Plaque Dispersion Score."

SAPPHIRE-WIN female study

Globally there are recognised challenges diagnosing coronary artery disease in women, which remains the number one killer of women globally. Unlike when men present with symptoms such as chest pain, women can often be asymptomatic and conventional risk stratification methods fail to identify high-risk women with non-obstructive coronary artery disease. This can result in missed opportunities for early intervention and treatment of these women.

Artrya intends to focus its upcoming SAPPHIRE study on the women with coronary artery disease, which will include a cohort of women only patients at risk, known as SAPPHIRE-WIN. The objective of SAPPHIRE-WIN will be to use the Salix® platform to assess a diverse range of women with non-obstructive coronary artery disease, to better predict the risk of material adverse coronary events and improve treatment outcomes.

SAPPHIRE Study expands with Dignity Health Arizona

Dignity Health Arizona's in-principle inclusion brings another distinguished, high-volume U.S. cardiology group into the upcoming SAPPHIRE Study, set to launch in 2026. This retrospective, multi-centre, real-world study will assess the clinical and prognostic value of Artrya's Salix® Plaque Analysis and its proprietary Plaque Dispersion Score, aiming to identify patients at elevated risk of cardiovascular events.

Dignity Health (part of CommonSpirit Health) is one of the largest nonprofit health care systems in the U.S. that operates more than 40 hospitals and 400 care centres across 21 states¹, including urgent and occupational care, imaging centres, home health, and primary care clinics. CommonSpirit is also recognised as a leader in cardiovascular care with 48 dedicated physicians in their cardiovascular medical and surgical team. Their cardiovascular program spans prevention, diagnosis and treatment and has completed over 30,000 interventional cardiology procedures, 250,000 cardiac catheterisations, 120,000 open heart procedures and 1,600 heart transplants².

- Ends -

¹ <https://www.dignityhealth.org/about-us>

² <https://commonspiritinternational.org/clinical-specialties/cardiovascular-services>

This ASX Announcement is authorised for release by the Board of Artrya Limited.

About Artrya

Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through innovative technology, with regulatory and commercial activities underway across key international markets.

For more information visit www.artrya.com or follow us on LinkedIn at www.linkedin.com/company/artrya

Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates** and **Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of Artrya. The Estimates and Projections are based on information available to Artrya as at the date of the Announcement, are based upon management’s current expectations, estimates, projections, assumptions and beliefs in regards to future events in respect to Artrya’s business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of Artrya and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by Artrya in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. Artrya takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.

For more information:

Corporate Enquiries

John Konstantopoulos

Co-Founder and Chief Executive Officer

Tel: +61 8 6478 7816

Email: contact@artrya.com

Investor & Media Enquiries

David Allen or John Granger

Hawkesbury Partners

Tel: +61 499 100 038 or +61 410 577 155

Email: investors@artrya.com